MTF’s AmnioBand™ Receives High-Tier Reimbursement from Medicare to Treat Chronic Non-Healing Wounds in the Hospital Outpatient Setting
EDISON, N.J., Sept. 16, 2015 /PRNewswire/ — MTF, the Musculoskeletal Transplant Foundation (www.mtf.org) announced today that beginning October 1, AmnioBand™ Allograft Placental Matrix will be placed in the high-tier reimbursement category for skin substitutes under the Centers for Medicare and Medicaid Services’ (CMS) Hospital Outpatient Prospective Payment System. With this designation hospital outpatient departments and affiliated wound care centers may now be able to receive a higher reimbursement when treating Medicare beneficiaries with AMNIOBAND for chronic non-healing wounds.
In Transmittal 3333, October 2015 Update of the Hospital Outpatient Prospective Payment System (OPPS),issued August 21, 2015 by CMS to its Medicare Administrative Contractors, CMS announced that they were reassigning AMNIOBAND “from the low cost skin substitute group to the high cost skin substitute group based on updated pricing information.”
“We are quite pleased that CMS has reassigned AMNIOBAND to the high-tier reimbursement category for skin substitutes used in the hospital outpatient setting. This higher Medicare reimbursement rate will better align with the costs hospital outpatient departments incur in treating complex wounds,” said Kim Rounds, Vice President of MTF Wound Care. “More importantly, this will enable MTF to further fulfill our mission to provide the gift of donated, high quality tissue to patients suffering from non-healing wounds,” Ms. Rounds noted.
AMNIOBAND, developed by the Musculoskeletal Transplant Foundation (MTF), is derived from dehydrated human placental membrane comprised of both the amnion and chorion layers. It is used as a scaffold for the treatment of chronic non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Studies have shown essential components present within AMNIOBAND support intrinsic wound healing functions, including providing a protective and physical barrier to infection, preventing bacteria infiltration, providing matrix proteins, and promoting tissue epithelization.
AMNIOBAND is aseptically processed, stored at ambient temperature in a ready to use “package to patient” configuration, and is available in a variety of sizes to prevent waste.
For a copy of CMS Transmittal 3333, please refer to the following link:
https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R3333CP.pdf
About MTF:
The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987, MTF has received tissue from more than 100,000 donors and distributed more than 6 million grafts for transplantation. For more information, visit www.mtf.org.
